[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100539177":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":32,"locations":40,"responsibleParty":67,"collaborators":69,"id":73,"slug":18,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":18,"enrollmentInfo":81,"targetDuration":18,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":42,"whyStopped":18,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Brigham and Women's Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Alert","EXPERIMENTAL","Alert-based CDS will consist of an on-screen electronic alert that will notify the clinician that the patient has an indication for LDL-C-lowering therapy but is not prescribed any. The clinician will have the opportunity to proceed to an order template through which appropriate lipid-lowering can be prescribed. The clinician could also elect to learn more about current evidence-based recommendations for LDL-C lowering in the PAD population. Finally, the clinician could elect to proceed without ordering oral LDL-C-lowering therapy or reading evidence-based recommendations for LDL-C lowering but would have to provide a rationale for not doing so.",[13],"Behavioral: Computer Alert",{"label":15,"type":16,"description":17,"interventionNames":18},"No Alert","NO_INTERVENTION","No on-screen notification will be issued to the clinician",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"BEHAVIORAL","Computer Alert","On-screen alert-based decision support raising awareness of need for lipid-lowering therapy in patients with peripheral artery disease",[9],[26],"EPIC Best Practice Advisory",[28],{"name":29,"affiliation":30,"role":31},"Gregory Piazza","BWH","PRINCIPAL_INVESTIGATOR",[33,37],{"name":29,"role":34,"phone":35,"phoneExt":18,"email":36},"CONTACT","6177326984","gpiazza@bwh.harvard.edu",{"name":38,"role":34,"phone":35,"phoneExt":18,"email":39},"Candrika D Kharaini","cdkhairani@@bwh.harvard.edu",[41],{"facility":5,"status":42,"city":43,"state":44,"zip":45,"country":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Boston","Massachusetts","02115","United States",{"type":48,"coordinates":49},"Point",[50,51],-71.05977,42.35843,{"lat":51,"lon":50},[54,57,59,60,63,65],{"name":55,"role":34,"phone":56,"phoneExt":18,"email":36},"Gregory Piazza, MD, MS","617-732-6984",{"name":18,"role":34,"phone":18,"phoneExt":58,"email":36},"Piazza",{"name":55,"role":31,"phone":18,"phoneExt":18,"email":18},{"name":61,"role":62,"phone":18,"phoneExt":18,"email":18},"Samuel Goldhaber, MD","SUB_INVESTIGATOR",{"name":64,"role":62,"phone":18,"phoneExt":18,"email":18},"Ron Blankstein, MD",{"name":66,"role":62,"phone":18,"phoneExt":18,"email":18},"Jorge Plutzky, MD",{"type":31,"investigatorFullName":55,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Associate Director, Thrombosis Research Group",[70],{"name":71,"class":72},"Esperion Therapeutics, Inc.","INDUSTRY","100539177",false,"NCT06300450","Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy","PAD-ALERT","Inclusion Criteria:\n\n* All patients ≥ 18 years old\n* Seen in Cardiovascular Medicine Clinic, Primary Care, Podiatry, Vascular Surgery, and Diabetology\n* Medical history entry, visit diagnosis, or problem list entry of PAD\n* Not prescribed LDL-C-lowering therapy\n\nExclusion Criteria:\n\n* Patients taking a statin, ezetimibe, bempedoic acid, a PCSK9 inhibitor, inclisiran or a combination will be excluded","ALL","18 Years",{"count":82,"type":83},400,"ESTIMATED","INTERVENTIONAL",[86],"NA","This single-center, 400-patient, randomized controlled trial assesses the impact of a patient- and provider-facing EPIC Best Practice Advisory (BPA; alert-based computerized decision support tool) to increase guideline-directed utilization of statin and statin-alternative oral LDL-C lowering therapies in patients with PAD who are not being prescribed LDL-C-lowering therapy.",[89,90,91],"Peripheral Artery Disease","Peripheral Vascular Diseases","Dyslipidemias",[93,89,94,95],"Dyslipidemia","Peripheral Vascular Disease","Computerized Decision Support","2026-06-16",{"date":98,"type":99},"2026-06-17","ACTUAL",{"date":101,"type":99},"2023-03-01",{"date":103,"type":83},"2026-12-30",{"name":5,"class":6},1]